Navigation Links
Isis Pharmaceuticals to Present at Jefferies' 3rd Annual Healthcare Conference
Date:6/11/2009

CARLSBAD, Calif., June 11 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Jefferies 3rd Annual Healthcare Conference on Wednesday, June 17, 2009, at 8:00 a.m. ET in New York.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular, metabolic and severe neurodegenerative diseases and cancer. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Dead or damaged trees can quickly turn into ... cases, tree removal by a skilled team is recommended as ... , In their latest article , Precision Tree ... property owners today. Each method requires skill and expertise that ... , The article states that, “Tree removal is not “one ...
(Date:4/28/2015)... Once considered an unproven alternative to HID lighting, the ... storm with perfectly tailored light spectrums in an ideal, low ... than half of every SuperCloset and SuperRoom sold are now ... is gone and LED Grow Lights are here to stay. ... their first hand experience using the new LED Grow lights ...
(Date:4/28/2015)... The Awareness Counselor team has introduced a new ... According to Awareness Counselor, there are ramifications of judging. Judging ... to an individual who self-judges. This new concept is now ... or one one one talk. , The premise of this ... that every being on earth is here for a purpose ...
(Date:4/28/2015)... April 28, 2015 LifeAID® ... and convenient nutrition for every lifestyle, announced ... through United Natural Foods Inc (UNFI), the ... and specialty foods including nutritional supplements. FitAID®, ... to thousands of retailers and consumers through ...
(Date:4/27/2015)... 27, 2015 Churchview Supportive Living, a ... Day Brunch and Fashion Show from 10:30 a.m. to ... located at 2626 W. 63rd St. in Chicago, serves ... some help to maintain their independence. , “Mothers, grandmothers, ... a Mother’s Day Brunch,” said Director of Marketing Elizabeth ...
Breaking Medicine News(10 mins):Health News:Tree Removal Methods and Services Discussed in Recent Article by Precision Tree Services 2Health News:SuperCloset Reports Surge in KIND LED Grow Light Sales, Saving Indoor Growing Enthusiasts up to 40% on their Power Usage. 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 2Health News:What Happens When We Judge Ourselves and Others? – A New Concept Introduced 3Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 2Health News:LifeAID Beverage Co. Announces Expanded Distribution Roll Out Through UNFI -- United Natural Foods Inc. 3Health News:Churchview Supportive Living Community in Chicago to Host Mother's Day Brunch 2
... studies to establish an effective treatment for Duchenne Muscular Dystrophy ... myostatin - a protein that inhibits muscle growth - might ... Wagner of John Hopkins University showed in a new study, ... DMD is increased by the loss of the myostatin gene. ...
... Every one of us knows and understands that happy relationships ... know that the continuous //tension of a distressed intimate relationship ... According to a new study by researchers in Canada, when ... heart health. ,The study which was conducted over a ...
... have boosted confidence in a method used to repair cardiac ... stem cells derived from bone marrow which is much less ... heart attack and had undergone conventional bypass therapy. ,Doctors ... heart attack were injected with bone marrow stem cells into ...
... one of the most common reason which results in ... common and potentially dangerous bug which causes this ... bacterium is found naturally in the environment and survives ... for long periods. This bacterium which is not harmful ...
... age people are now increasingly taking to gardening as a ... of beautiful gardens. Though gardening has been proven to have ... gardeners who start with little or no idea of how ... up having severe back pain. ,A recent study of ...
... fall at least once in our life. But how many of ... not even a few of us. But researchers at the Locomotion ... a fall// will help prevent them better. The researchers, who claim ... institutionalized or even die due to a fall, have taken up ...
Cached Medicine News:Health News:Myostatin gene could hold the key to treatment for DMD 2Health News:Unhappy relationships could result in more than just heart breaks! 2Health News:Machines take over the battle against hospital bugs 2
(Date:4/27/2015)...   Intarcia Therapeutics, Inc. today announced the ... an equity conversion option at a $5.5 billion Company ... the initiation of additional head-to-head comparative and switch studies ... 2 diabetes therapies. In addition, proceeds from the financing ... launch ITCA 650 in the United States ...
(Date:4/27/2015)... 2015 Array BioPharma Inc. (Nasdaq: ... third quarter of fiscal 2015 and hold ... on Monday, May 4, 2015.  Ron Squarer, ... May 4, 2015Time:9:00 a.m. Eastern TimeToll-Free:(844) 464-3927Toll:(765) ... Conference Call Slides:  http://edge.media-server.com/m/p/8tsxszuw/lan/en ...
(Date:4/27/2015)... THE WOODLANDS, Texas , April 27, 2015 /PRNewswire/ ... a biopharmaceutical company focused on developing breakthrough treatments for ... results on Wednesday, April 29, 2015 after the financial ... and webcast to discuss clinical development progress and financial ... Eastern Time on April 29, 2015. The ...
Breaking Medicine Technology:Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 2Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation 3Lexicon To Report First Quarter 2015 Financial Results On April 29, 2015 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: